Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
US-9233171-B2 · Jan 12, 2016 · US
Antibodies selective for cells presenting EGFR at high density
US10570211B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10570211-B2 |
| Application number | US-201213821832-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 20, 2012 |
| Priority date | Jan 24, 2011 |
| Publication date | Feb 25, 2020 |
| Grant date | Feb 25, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
First claim
Opening claim text (preview).
We claim: 1. An epidermal growth factor receptor (EGFR) antibody, wherein the EGFR antibody is selected from the group consisting of: (a) an EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises complementarity determining regions CDR1 having the amino acid sequences of NYGVH (SEQ ID NO: 1), CDR2 having the amino acid sequences of VIWSGGNTD 58 YNTPFTS (SEQ ID NO: 2), and CDR3 having the amino acid sequences of ALTY 101 Y 102 D 103 YE 105 FAY (SEQ ID NO: 3), and wherein the light chain comprises complementarity determining regions CDR1 having the amino acid sequences of RASQSIGTNIH (SEQ ID NO: 4), CDR2 having the amino acid sequences of ASE 53 SIS (SEQ ID NO: 5), wherein E 53 is substituted by K 53 , and CDR3 having the amino acid sequences of QQNNNW 94 PTT (SEQ ID NO: 6); (b) an EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises complementarity determining regions CDR1 having the amino acid sequences of NYGVH (SEQ ID NO: 1), CDR2 having the amino acid sequences of VIWSGGNTD 58 YNTPFTS(SEQ ID NO: 2), and CDR3 having the amino acid sequences of ALTY 101 y 102 D 103 YE 105 FAY (SEQ ID NO: 3), and wherein the light chain comprises complementarity determining regions CDR1 having the amino acid sequences of RASQSIGTNIH (SEQ ID NO: 4), CDR2 having the amino acid sequences of ASE 53 SIS (SEQ ID NO: 5), and CDR3 having the amino acid sequences of QQNNNW 94 PTT(SEQ ID NO: 6), wherein W 94 is substituted by A 94 ; (c) an EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises complementarity determining regions CDR1 having the amino acid sequences of NYGVH (SEQ ID NO: 1), CDR2 having the amino acid sequences of VIWSGGNTD 58 YNTPFTS (SEQ ID NO: 2), and CDR3 having the amino acid sequences of ALTY 101 Y 102 D 103 YE 105 FAY (SEQ ID NO: 3), wherein Y 101 is substituted by A 101 , and wherein the light chain comprises complementarity determining regions CDR1 having the amino acid sequences of RASQSIGTNIH (SEQ ID NO: 4), CDR2 having the amino acid sequences of ASE 53 SIS(SEQ ID NO: 5), and CDR3 having the amino acid sequences of QQNNNW 94 PTT (SEQ ID NO: 6), (d) an EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises complementarity determining regions CDR1 having the amino acid sequences of NYGVH (SEQ ID NO: 1), CDR2 having the amino acid sequences of VIWSGGNTD 58 YNTPFTS (SEQ ID NO: 2), and CDR3 having the amino acid sequences of ALTY 101 Y 102 D 103 YE 105 FAY (SEQ ID NO: 3), wherein Y 101 is substituted by A 101 , and wherein the light chain comprises complementarity determining regions CDR1 having the amino acid sequences of RASQSIGTNIH (SEQ ID NO: 4), CDR2 having the amino acid sequences of ASE 53 SIS(SEQ ID NO: 5), wherein E 53 is substituted by K 53 , and CDR3 having the amino acid sequences of QQNNNW 94 PTT(SEQ ID NO: 6); (e) an EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises complementarity determining regions CDR1 having the amino acid sequences of NYGVH (SEQ ID NO: 1), CDR2 having the amino acid sequences of VIWSGGNTD 58 YNTPFTS (SEQ ID NO: 2), and CDR3 having the amino acid sequences of ALTY 101 Y 102 D 103 YE 105 FAY (SEQ ID NO: 3), wherein Y 101 is substituted by A 101 , and wherein the light chain comprises complementarity determining regions CDR1 having the amino acid sequences of RASQSIGTNIH (SEQ ID NO: 4), CDR2 having the amino acid sequences of ASE 53 SIS(SEQ ID NO: 5), and CDR3 having the amino acid sequences of QQNNNW 94 PTT (SEQ ID NO: 6), wherein W 94 is substituted by A 94 ; (f) an EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises complementarity determining regions CDR1 having the amino acid sequences of NYGVH (SEQ ID NO: 1), CDR2 having the amino acid sequences of VIWSGGNTD 58 YNTPFTS (SEQ ID NO: 2), and CDR3 having the amino acid sequences of ALTY 101 Y 102 D 103 YE 105 FAY (SEQ ID NO: 3), wherein Y 102 is substituted by A 102 , and wherein the light chain comprises complementarity determining regions CDR1 having the amino acid sequences of RASQSIGTNIH (SEQ ID NO: 4), CDR2 having the amino acid sequences of ASE 53 SIS(SEQ ID NO: 5), and CDR3 having the amino acid sequences of QQNNNW 94 PTT (SEQ ID NO: 6); (g) an EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises complementarity determining regions CDR1 having the amino acid sequences of NYGVH (SEQ ID NO: 1), CDR2 having the amino acid sequences of VIWSGGNTD 58 YNTPFTS (SEQ ID NO: 2), and CDR3 having the amino acid sequences of ALTY 101 Y 102 D 103 YE 105 FAY (SEQ ID NO: 3), wherein Y 102 is substituted by A 102 , and wherein the light chain comprises complementarity determining regions CDR1 having the amino acid sequences of RASQSIGTNIH (SEQ ID NO: 4), CDR2 having the amino acid sequences of ASE 53 SIS(SEQ ID NO: 5), wherein E 53 is substituted by K 53 , and CDR3 having the amino acid sequences of QQNNNW 94 PTT(SEQ ID NO: 6); (h) an EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises complementarity determining regions CDR1 having the amino acid sequences of NYGVH (SEQ ID NO: 1), CDR2 having the amino acid sequences of VIWSGGNTD 58 YNTPFTS (SEQ ID NO: 2), and CDR3 having the amino acid sequences of ALTY 101 Y 102 D 103 YE 105 FAY (SEQ ID NO: 3), wherein Y 102 is substituted by A 102 , and wherein the light chain comprises complementarity determining regions CDR1 having the amino acid sequences of RASQSIGTNIH (SEQ ID NO: 4), CDR2 having the amino acid sequences of ASE 53 SIS(SEQ ID NO: 5), and CDR3 having the amino acid sequences of QQNNNW 94 PTT(SEQ ID NO: 6), wherein W 94 is substituted by A 94 ; (i) an EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises complementarity determining regions CDR1 having the amino acid sequences of NYGVH (SEQ ID NO: 1), CDR2 having the amino acid sequences of VIWSGGNTD 58 YNTPFTS (SEQ ID NO: 2), and CDR3 having the amino acid sequences of ALTY 101 Y 102 D 103 YE 105 FAY (SEQ ID NO: 3), wherein D 103 is substituted by N 103 , and wherein the light chain comprises complementarity determining regions CDR1 having the amino acid sequences of RASQSIGTNIH (SEQ ID NO: 4), CDR2 having the amino acid sequences of ASE 53 SIS(SEQ ID NO: 5), and CDR3 having the amino acid sequences of QQNNNW 94 PTT (SEQ ID NO: 6); (j) an EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises complementarity determining regions CDR1 having the amino acid sequences of NYGVH (SEQ ID NO: 1), CDR2 having the amino acid sequences of VIWSGGNTD 58 YNTPFTS (SEQ ID NO: 2, and CDR3 having the amino acid sequences of ALTY 101 Y 102 D 103 YE 105 FAY (SEQ ID NO: 3), wherein D 103 is substituted by N 103 , and wherein the light chain comprises complementarity determining regions CDR1 having the amino acid sequences of RASQSIGTNIH (SEQ ID NO: 4), CDR2 having the amino acid sequences of ASE 53 SIS(SEQ ID NO: 5), wherein E 53 is substituted by K 53 , and CDR3 having the amino acid sequences of QQNNNW 94 PTT(SEQ ID NO: 6); (k) an EGFR antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises complementarity determining regions CDR1 having the amino acid sequences of NYGVH (SEQ ID NO: 1), CDR2 having the amino acid sequences of VIWSGGNTD 58 YNTPFTS (SEQ ID NO: 2), and CDR3 having the amino acid sequences of ALTY 101 Y 102 D 103 YE 105 FAY (SEQ ID NO: 3), wherein D 103 is substituted by N 103 , and wherein the light chain comprises complementarity determining regions CDR1 having the amino acid sequences of RASQSIGTNIH (SEQ ID NO: 4), CDR2 having the amino acid sequences of ASE 53 SIS(SEQ ID NO: 5), and CDR3 having the amino acid sequences of QQNNNW 94 PTT (SEQ ID NO: 6), wherein W 94 is substituted by A 94 ; (l) an EGFR antibody com
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Framework region [FR] · CPC title
- C07K16/2863Primary
against receptors for growth factors, growth regulators · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Complementarity determining region [CDR] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10570211B2 cover?
- Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
- Who is the assignee on this patent?
- Tikhomirov Ilia Alexandre, Jaramillo Maria L, OCONNOR MCCOURT Maureen D, and 8 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2863. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).